The Day

Study: COVID poses greater risk of clots

Odds 8-10 times higher than after vaccinatio­n

- By TODD GILLESPIE

The risk of blood clots among those who’ve been diagnosed with COVID-19 is higher than among those who’ve received vaccines against the disease, according to a new study from the University of Oxford.

COVID patients saw a clot risk of 39 in a million. That compared with four in a million in mRNA vaccines like those developed by Pfizer and BioNTech or Moderna, and five in a million people after AstraZenec­a’s vaccine. Though the analyses for the three vaccines are based on different data sets, making comparison­s difficult, the study suggests that the risk of a clot among those with the disease is about eight to 10 times higher than after vaccinatio­n.

“All the evidence we have is that risks of COVID are so much greater than whatever the risks of the vaccines might be,” Paul Harrison, professor of psychiatry at Oxford and one of the study’s authors, said in a briefing. “And unfortunat­ely you might think you’re not going to catch it, but I think everybody would agree there’s a risk of catching COVID in the current climate.”

It was hard to compare the baseline risk of clotting in the general population without COVID because incidence is rare and varies across age groups, the authors said in a news briefing.

Regulators in the U.K. and the European Union have placed restric

tions on the use of the AstraZenec­a vaccine, while shots of a separate inoculatio­n from Johnson & Johnson have been placed on hold in much of the world, amid concern over an associatio­n with the rare clots. The relative benefits of the AstraZenec­a shot, compared with the risk of clots, decrease when doses are given to younger adults, according to an analysis by the U.K.’s Medicines and Healthcare Products Regulatory Agency.

The authors of the Oxford study counted the number of cerebral venous thrombosis cases diagnosed in the two weeks after COVID diagnosis and after the first dose of a vaccine.

The authors aren’t associated with the Oxford Vaccine Group, which helped develop the AstraZenec­a vaccine.

Newspapers in English

Newspapers from United States